Shots:
- Relation has entered into a multi-program, strategic collaboration with Novartis to identify & advance novel targets for atopic diseases, leveraging Relation’s Lab-in-the-Loop platform
- As per the deal, Relation will lead patient-derived observational studies to create high-resolution functional cell atlases, while Novartis will secure global development & commercialization rights to any resulting targets
- In return, Relation will receive $55M, incl. an upfront payment, equity investment & additional R&D funding, with ~$1.7B in preclinical, development, regulatory, & commercial milestones, plus net sales-based tiered royalties
Ref: Globe Newswire | Image: Novartis & Relation | Press Release
Related News: Novartis to Acquire Avidity Biosciences for ~$12B, Boosting its Neuroscience Pipeline
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
